FDA Issues Safety Alert for Fluid-Filled Intragastric Balloons

Share this content:
FDA Issues Safety Alert for Fluid-Filled Intragastric Balloons
FDA Issues Safety Alert for Fluid-Filled Intragastric Balloons

MONDAY, Feb. 13, 2017 (HealthDay News) -- Fluid-filled intragastric balloons used to treat obesity have been linked to two different types of adverse events, according to the U.S. Food and Drug Administration.

Two types of fluid-filled balloon systems -- the ReShape Integrated Dual Balloon System and the Orbera Intragastric Balloon System -- were approved by the FDA in 2015. In a recent warning sent to health care providers, the FDA said it has received multiple reports of complications associated with the two balloon systems.

One adverse event reported is spontaneous hyperinflation resulting in the need for premature removal of the balloons. The second adverse event reported is development of acute pancreatitis, also resulting in need for device removal. The report notes acute pancreatitis developed in several patients due to the compression of gastrointestinal structures, and the condition can occur as soon as three days after implantation.

The FDA letter recommends that health care providers "closely monitor patients with these devices for these adverse events, and to submit reports to help us better understand any complications from the use of these obesity treatment devices." The agency said it is working with the manufacturers to better understand the problems caused by the fluid-filled balloon systems. The FDA said it will provide more information as the investigation continues. No problems have been reported with another type of balloon system used to treat obesity -- the Obalon system -- which uses only air, according to the FDA.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »